UMBRAL ENERGY CORP.

Condensed Interim Consolidated Financial Statements

For the three and nine month periods ended July 31, 2017 (Stated in Canadian Dollars)

(Unaudited)

Umbral Energy Corp.

Condensed Interim Consolidated Statements of Financial Position

(Stated in Canadian Dollars)

(Unaudited)

| 310,844 \$ 3,699 183,857 <u>170,000</u> 668,400 701,124 - | \$ 85,057 2,909 96,231 - - - - - - - - - - - - - - - - - - - |
|---|---|
| 3,699 183,857 <u>170,000</u> 668,400 | 2,909 96,231 - - - - - - - - - - - - - - - - - - - |
| 3,699 183,857 <u>170,000</u> 668,400 | 2,909 96,231 - - - - - - - - - - - - - - - - - - - |
| 183,857 <u>170,000</u> 668,400 | 96,231 - 184,197 433,914 146,350 |
| 170,000 668,400 | 184,197 433,914 146,350 |
| 668,400 | 433,914 146,350 |
| · | 433,914 146,350 |
| 701,124 _ | 146,350 |
| - | |
| | \$ 764,461 |
| 369,524 \$ | |
| | |
| 470.005 | ¢ |
| 172,685 \$ 69,927 | \$ 223,093 |
| 100,578 | 69,927 102,278 |
| 343,190 | 395,298 |
| 545,190 | 395,296 |
| | |
| 075,238 | 6,067,501 |
| 550,738 | 674,170 |
| 193,200 | - |
| 812,842) | (6,372,508) |
| | - |
| 20,000 | 369,163 |
| , | \$ 764,461 |
| Ì | |

Approved on behalf of the Board of Directors:

| "Jagdip Bal" | "Clint Sharples" |
|--------------|------------------|
| Director | Director |

Umbral Energy Corp. Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Stated in Canadian Dollars) (Unaudited)

| | Three Month | Three Month | Nine Month | Nine Month |
|--|----------------|--------------|----------------------|--------------|
| | Period Ended | Period Ended | Period Ended | Period Ended |
| | July 31, | July 31, | July 31, | July 31, |
| | 2017 | 2016 | 2017 | 2016 |
| | \$ | \$ | \$ | \$ |
| GENERAL AND ADMINISTRATIVE EXPENSES | | | | |
| Advertising, travel and promotion | 17,068 | 27,408 | 100,793 | 27,408 |
| Consulting fees (Note 8) | 130,517 | 24,053 | 337,864 | 115,235 |
| Management fees (Note 8) | 15,000 | 25,000 | 60,390 | 67,381 |
| Office expense and miscellaneous | 1,617 | 9 | 3,482 | 6,269 |
| Professional fees | 4,391 | 13,547 | 27,054 | 19,260 |
| Regulatory fees | 1,757 | 4,213 | 7,497 | 7,213 |
| Shareholder communications | 4,984 | 4,266 | 15,784 | 5,866 |
| Stock-based compensation | 278,662 | 466,293 | 744,972 | 588,835 |
| Transfer agent and shareholder | | | | |
| information | 8,596 | 8,475 | 12,952 | 13,031 |
| Total general and administrative | | | | |
| expenses | 462,592 | 573,264 | 1,310,788 | 850,498 |
| Loss from operations | (462,592) | (573,264) | (1,310,788) | (850,498) |
| Other items Equity loss on investment of associate Loss on sale of mineral properties | (38,380) 45 | (37) | (60,495) (69,051) | (112) |
| NET LOSS FOR THE PERIOD | (500,927) | (573,301) | (1,440,334) | (850,610) |
| Other comprehensive income/(loss) Items that may be reclassified subsequently to profit or loss Fair value gain/(loss) on available- for-sale investment | (60,000) | | 20,000 | |
| | (00,000) | | 20,000 | |
| TOTAL COMPREHENSIVE LOSS FOR THE PERIOD | (560,927) | (573,301) | (1,420,334) | (850,610) |
| Basic and diluted loss per common share | (0.01) | (0.01) | (0.02) | (0.02) |
| Weighted average number of common shares outstanding | 78,080,291 | 58,201,304 | 71,292,826 | 54,366,003 |

Umbral Energy Corp. Condensed Interim Consolidated Statements of Changes in Equity (Stated in Canadian Dollars) (Unaudited)

Nine Month Periods Ended July 31, 2017, 2016 and Year Ended October 31, 2016

| | SHARE | СА | PITAL | | ARE-BASED PAYMENT | SU | SHARE BSCRIPTION | | ACCUMULUTED OTHER COMPREHENSIVE | |
|---|------------|----|-----------|----|----------------------|----|---------------------|----------------|---------------------------------------|-----------------|
| | NUMBER | | AMOUNT | F | RESERVE | R | ECEIVABLE | DEFICIT | INCOME/(LOSS) | TOTAL |
| Balance, October 31, 2015 Issued for cash | 51,966,972 | \$ | 5,061,580 | \$ | 461,841 | \$ | (56,750) | \$ (5,342,815) | \$- | \$ 123,856 |
| Share options exercised | 6,985,000 | | 744,129 | | (359,079) | | - | - | - | 385,050 |
| Warrants exercised | 1,790,174 | | 107,410 | | - | | - | - | - | 107,410 |
| Share subscription receivable (Note 7) | - | | - | | - | | 46,750 | - | - | 46,750 |
| Stock based compensation | - | | - | | 588,835 | | - | | - | 588,835 |
| Net loss for the period | - | | - | | - | | - | (850,609) | - | (850,609) |
| Balance, July 31, 2016 Issued shares for cash | 60,742,146 | \$ | 5,913,119 | \$ | 691,597 | \$ | (10,000) | \$ (6,193,424) | \$- | \$ 401,292 |
| Share options exercised | 1,100,000 | | 101,882 | | (46,882) | | - | - | - | 55,000 |
| Shares issued on acquisition | 1,500,000 | | 52,500 | | - | | - | - | - | 52,500 |
| Share subscription receivable (Note 7) | - | | - | | - | | 10,000 | - | - | 10,000 |
| Stock based compensation | - | | - | | 29,455 | | - | - | - | 29,455 |
| Net loss for the period | | | - | | - | | - | (179,084) | - | (179,084) |
| Balance, October 31, 2016 Issued shares for cash | 63,342,146 | \$ | 6,067,501 | \$ | 674,170 | \$ | - | \$ (6,372,508) | \$- | \$ 369,163 |
| Share options exercised | 12,730,000 | | 1,729,904 | | (868,404) | | - | - | - | 861,500 |
| Warrants exercised | 2,419,826 | | 165,333 | | (, , | | - | - | - | 165,333 |
| Shares issued for mineral property | 1,500,000 | | 112,500 | | | | - | - | - | 112,500 |
| Stock based compensation | - | | - | | 744,972 | | - | - | - | 744,972 |
| Shares subscribed | - | | - | | - | | 193,200 | - | - | 193,200 |
| Unrealized gain on investments | - | | - | | - | | - | - | 20,000 | 20,000 |
| Net loss for the period | | | - | | - | | - | (1,440,334) | - | (1,440,334) |
| Balance, July 31, 2017 | 79,991,972 | \$ | 8,075,238 | \$ | 550,738 | \$ | 193,200 | \$ (7,812,842) | \$ 20,000 | \$ 1,026,334 |

Umbral Energy Corp. Condensed Interim Consolidated Statements of Cash Flows

(Stated in Canadian Dollars)

(Unaudited)

| 2017 (1,440,334) 60,495 744,972 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | ¥ 31, \$ | 2016 (850,609) 112 588,835 - 1,962 (132,873) 17,156 (7,812) (383,229) - (59,793) |
|--|-------------|---|
| 60,495 744,972 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | \$ | 112 588,835 - (132,873) (17,156 (7,812) (383,229) |
| 60,495 744,972 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | \$ | 112 588,835 - (132,873) (17,156 (7,812) (383,229) |
| 60,495 744,972 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | • | 112 588,835 - (132,873) (17,156 (7,812) (383,229) |
| 744,972 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | | 588,835 - 1,962 (132,873) 17,156 (7,812) (383,229) |
| 744,972 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | | 588,835 - 1,962 (132,873) 17,156 (7,812) (383,229) |
| 69,051 (790) (87,626) (50,408) - (704,640) (327,705) 39,799 | | 1,962 (132,873) 17,156 (7,812) (383,229) |
| (790) (87,626) (50,408) (704,640) (327,705) 39,799 | | (132,873) 17,156 (7,812) (383,229) |
| (87,626) (50,408) - (704,640) (327,705) 39,799 | | (132,873) 17,156 (7,812) (383,229) |
| (87,626) (50,408) - (704,640) (327,705) 39,799 | | (132,873) 17,156 (7,812) (383,229) |
| (50,408) (704,640) (327,705) 39,799 | | 17,156 (7,812) (383,229) |
| (704,640) (327,705) 39,799 | | (7,812) (383,229) |
| (327,705) 39,799 | | (383,229) |
| (327,705) 39,799 | | |
| (007 000) | | |
| (287,906) | | (59,793 |
| | | |
| | | |
| • • • | | - |
| • | | |
| 1,026,833 | | 539,210 |
| 1,218,333 | | 539,210 |
| 225,787 | | 96,188 |
| 85,057 | | 11,806 |
| 310.844 | \$ | 107,994 |
| | 225,787 | 193,200 1,026,833 1,218,333 225,787 85,057 |

Non-cash Investing and Financing Transactions (Note 9)

1. Nature of Operations and Going Concern

The Company is a development stage public company whose common shares trade on the Canadian Securities Exchange under the symbol "UMB.C" The Company was incorporated on October 25, 2007 in British Columbia, Canada, under the Business Corporations Act and commenced operations on November 1, 2007. The head office and principal address of the Company is 929 Mainland Street, Vancouver, British Columbia, Canada V6C 2B3 and the registered and records office of the Company is located at Suite 1500-1055 West Georgia St., Vancouver, B.C., V6E 4N7.

The Company is principally engaged in the acquisition, exploration, and development of resource properties. The Company also participates in, through its joint venture investment of PhyeinMed Inc., which has submitted an application to acquire a Health Canada license under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") for the purpose of entering the medical marijuana industry.

Although the Company has started to invest resources for a medical marijuana business, there is no guarantee the Company will be awarded a license to grow medical marijuana. As the Company does not yet have cash flow from operations, it must rely on equity financing to fund operations. To date the Company's main source of funding has been the issuance of equity securities for cash, through private placements to sophisticated investors and through public offering to institutional investors. The Company has historically raised operating capital from the sale of equity, and will continue to do so.

The condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. This assumes the Company will operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company has incurred operating losses since inception, does not have positive operating cash flow, and there can be no assurances that sufficient funding, including adequate financing, will be available to explore its mineral properties, develop its ACMPR business plans and to cover general and administrative expenses necessary for the maintenance of a public company. The ability of the Company to arrange additional financing in the future depends in part, on the prevailing capital market conditions, resource property exploration success and its progress on obtaining an ACMPR license. These factors may cast significant doubt on the Company's ability to continue as a going concern. Accordingly, the condensed interim consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and liquidate its liabilities, contingent obligations and commitments other than in the normal course of business and at amounts different from those in these consolidated financial statements.

2. Basis of Presentation

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB ("International Accounting Standards Board") applicable to the preparation of condensed interim consolidated financial statements, including International Accounting Standard ("IAS") 34 - Interim Financial Reporting. The accounting policies followed in these condensed interim consolidated financial statements are the same as those applied in the Company's audited annual financial statements for the year ended October 31, 2016.

2. Basis of Presentation (Continued)

These condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, 1005477 B.C. Ltd. and Umbral Energy LLC (Washington State). The condensed interim financial statements of the subsidiaries are prepared using consistent accounting policies and reporting dates of the Company. All inter-company transactions and accounts have been eliminated upon consolidation.

The policies applied in these condensed interim consolidated financial statements are based on IFRS issued and outstanding as of September 27, 2017, the date the Audit Committee approved the statements. Any subsequent changes to IFRS after this date could result in changes to the condensed interim consolidated financial statements for the period ended July 31, 2017. The condensed interim consolidated financial statements do not contain all disclosures required under IFRS and should be read in conjunction with Company's annual financial statements and the notes thereto for the year ended October 31, 2016.

The preparation of condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosures of contingent assets and contingent liabilities at the date of the condensed interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed interim consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the condensed interim consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods. Actual results could differ from those estimates. Significant accounts that require estimates as the basis for determining the stated amounts include but are not limited to exploration and evaluation assets, oil and gas interests, share-based payments, allocation of financing proceeds, and income and mining taxes. Differences may be material.

3. Prepaid Expenses and Deposits

The Company's current prepaid expenses and advances consist mainly of ACMPR growing, marketing and distribution consulting fees paid in advance of services.

| | July 31, 2017 | October 31, 2016 |
|---|------------------|---------------------|
| ACMPR growing, marketing and distribution consulting fees | \$ 182,291 | \$ - |
| Digital marketing contract | - | 95,931 |
| Others | 1,566 | 300 |
| | \$ 183,857 | \$ 96,231 |

4. Marketable Securities

During the period ended July 31, 2017, the Company received 2,000,000 common shares of Equitorial Exploration Corp. ("Equitorial") in accordance with the assignment agreement of the Tule Valley and Gerlach Projects (see Note 6). The shares were valued at \$0.075 on the date they were issued to the Company. The fair market value at July 31, 2017 was \$170,000 or \$0.085 per common share. The Company has recorded a temporary fair value gain of \$20,000.

5. Investment in Joint Venture and Advances

| | July 31, | October 31, |
|-----------------------------|---------------|---------------|
| | 2017 | 2016 |
| Investment in joint venture | \$ 179,160 | \$ 189,654 |
| Advances to joint venture | 521,964 | 244,260 |
| | \$ 701,124 | \$ 433,914 |

The Company holds all the issued and outstanding shares of 1005477 B.C. Ltd., a holding company which owns 50% of the common shares of PhyeinMed Inc. ("PhyeinMed"), an operating company incorporated in British Columbia which has submitted an application to Health Canada for a Marihuana for Medical Purposes Regulations license. Management determined that the 50% interest in PhyeinMed is a joint venture under IFRS 11 as Umbral management has no control over strategic, financial, permitting, development or operating decisions of PhyeinMed. The investment in the joint venture is accounted for using the equity method.

On June 21, 2017, the Company entered into an agreement to acquire an additional 25% interest of the issued and outstanding shares of PhyeinMed Inc. to total a 75% interest. Subsequent to July 31, 2017, the Company completed the acquisition. See Subsequent Event Note 10.

The continuity of this investment of the joint venture prior to acquiring a control position is as follows:

| | N | INE MONTH | N | NE MONTH |
|--|----|------------|----|------------|
| | PE | RIOD ENDED | PE | RIOD ENDED |
| | | JULY 31, | | JULY 31, |
| | | 2017 | | 2016 |
| Balance, beginning of the period | \$ | 189,655 | \$ | 194,406 |
| Increase in equity investment, cash | | 50,000 | | - |
| Equity loss on investment in joint venture | | (60,495) | | (112) |
| Balance, end of the period | \$ | 179,160 | \$ | 194,294 |

5. Investment in Joint Venture and Advances (Continued)

Summary financial information of the investment of the joint venture is as follows:

| Statements of Financial Position | July 31, 2017 | October 31, 2016 |
|---|--|--------------------------------|
| Total Assets | \$ 172,139 | \$ 13,431 |
| Current Liabilities Advances from Joint Venture Partner Shareholders' Deficiency | 36,501 521,964 (386,326) | 34,509 373,759 (394,837) |
| Total liabilities and shareholders' deficiency | \$ 172,139 | \$ 13,431 |
| Statements of Comprehensive Loss | NINE MON ENDEI 2017 | |
| Expenses | \$ 120,989 | \$ 112 |
| Comprehensive loss for the period | \$ 120,989 | \$ 112 |
| Statements of Cash Flow | NINE MON ENDED 2017 | |
| Comprehensive loss for the period Changes in non-cash operating assets and liabilities GST receivable Deposits Accounts payable and accrued liabilities | \$ (120,989) (5,296) (103,000) 1,993 | \$ (112) - - - |
| Cash Used in Operating Activities Cash Used in Investing Activities Cash Provided by Financing Activities | (227,292) - 277,704 | (112) - - |
| Change In Cash | 50,412 | (112) |
| Cash, Beginning Of Period | - | 222 |
| Cash, End Of Period | \$ 50,412 | \$ 110 |

5. Investment in Joint Venture and Advances (Continued)

b) Advances

During the year ended October 31, 2015 the Company entered into a loan agreement whereby the Company will advance up to \$5,000,000 to PhyeinMed for working capital purposes. The advances are unsecured and are due within 36 months from the date of the advance. The first \$550,000 advanced does not accrue interest prior to 36 months from the date of the advance after which interest shall be accrued at prime plus 2%. All advances subsequent to the initial \$550,000 will accrue interest at prime plus 2% from the date of the advance. PhyeinMed can only repay the initial \$550,000 advanced as follows:

- a) \$25,000 once an application for a medical marihuana growing operation is awarded to PhyeinMed by Health Canada;
- b) \$150,000 once the final ACMPR license is awarded to PhyeinMed by Health Canada;
- c) \$150,000 once PhyeinMed has achieved an accumulated EBITDA of \$1,000,000; and
- d) \$225,000 once PhyeinMed has achieved an accumulated EBITDA of \$2,000,000.

Subsequent to July 31, 2017, the Company committed up to an additional \$3,000,000 to fund PhyeinMed's efforts in the medical marijuana business to total \$8,000,000.

| | Nine month period ended July 31, 2017 | | Year ended October 31, 2016 |
|---|--|-------------------------------------|---------------------------------------|
| Acquisition Costs: Balance, beginning of period Cash payment Shares issued | \$ | 112,500 100,000 112,500 | \$ - 60,000 52,500 |
| Balance, end of period | | 325,000 | 112,500 |
| Exploration Costs: Balance, beginning of period Assaying and geochemical Claim fees Geological consulting, surveys and reports Travel, supplies and field expenses | | 33,850 - 52,271 2,541 - | - 975 6,964 14,930 10,981 |
| Balance, end of period | | 88,662 | 33,850 |
| Less: Cash received Deemed fair value of shares received | | 194,611 150,000 | - |
| Total sale proceeds | | 344,611 | - |
| Loss on sale of exploration and evaluation assets | | (69,051) | - |
| Total Acquisition and Exploration Costs | \$ | - | \$ 146,350 |

6. Exploration and Evaluation Assets

6. Exploration and Evaluation Assets (Continued)

Tule Valley Project, Utah and Gerlach Project, Nevada

Pursuant to a property purchase agreement dated April 20, 2016, the Company was granted the right to acquire an undivided 100% interest in 26 contiguous mineral claims totaling 4,800 acres located in Millard County, Utah known as the Tule Valley Project and a further 89 contiguous mineral claims totaling 1,780 acres located in Washoe County, Nevada known as the Gerlach Project.

As consideration for the properties, the Company made the following cash payments and issued the following shares:

| | CASH <u>PAYMENTS</u> | COMMON <u>SHARES</u> |
|--------------------------------|-------------------------|-------------------------|
| On signing of option agreement | | |
| April 20, 2016 | \$ 10,000 | 1,500,000 |
| On or before June 20, 2016 | 20,000 | Nil |
| On or before July 20, 2016 | 30,000 | Nil |
| On or before April 20, 2017 | 100,000 | <u>1,500,000</u> |
| | <u>\$ 160,000</u> | 3,000,000 |

The properties are subject to a net smelter return royalty of 2%. The Company has an option to purchase 1% of the 2% net smelter return royalty for \$1,000,000 at any time.

During the period ended July 31, 2017, the Company entered into an assignment agreement with Equitorial Exploration Corp., an arm's length party, to assign the Company's right, title and interest of the Tule Valley and Gerlach Projects. Under the terms of the Assignment Agreement, Equitorial paid \$150,000 plus claim staking costs of \$44,611 and issued 2,000,000 common shares upon closing at a deemed value of \$0.075 per common share (April 7, 2017, the date of closing). The Company recorded a \$69,051 loss on the sale of the property.

7. Share Capital and Reserve

a) Authorized

Unlimited number of common shares without par value

b) Issued

Nine month period ended July 31, 2017:

The Company issued 12,730,000 common shares for the exercise of 12,730,000 stock options at prices between \$0.05 and \$0.08 per share for total proceeds of \$861,500 which resulted in the transfer from share-based payment reserve to share capital of \$868,404. The Company issued 2,419,826 common shares for the exercise of 2,419,826 warrants at prices of \$0.06 and \$0.10 per share for total proceeds of \$165,333.

The Company issued 1,500,000 common shares with a fair value of \$112,500 measured on the date of issuance in accordance with the option agreement for the right to acquire an interest in the Tule Valley and Gerlach Lithium properties (See Note 6).

7. Share Capital and Reserve (Continued)

Year ended October 31, 2016:

The Company issued 8,085,000 common shares for the exercise of 8,085,000 stock options between \$0.05 and \$0.08 per share for total proceeds of \$440,050 which resulted in a transfer from share-based payment reserve to share capital of \$405,961. The Company issued 1,790,174 common shares for the exercise of 1,790,174 warrants at \$0.06 per share for total proceeds of \$107,410.

The Company issued 1,500,000 common shares with a fair value of \$52,500 measured on the date of issuance in accordance with the option agreement for the right to acquire an interest in the Tule Valley and Gerlach Lithium properties (Note 6).

c) Warrants

The following is a summary of the changes in warrants:

| | NUMBER OF WARRANTS | WEIGHTED AVERAGE EXERCISE PRICE |
|---------------------------|-----------------------|------------------------------------|
| Balance, October 31, 2015 | 13,635,400 | \$0.06 |
| Exercised | (1,790,174) | 0.06 |
| Balance, October 31, 2016 | 11,845,226 | \$0.06 |
| Exercised | (2,419,826) | 0.07 |
| Balance, July 31, 2017 | 9,425,400 | \$0.06 |

The following table summarizes the warrants outstanding and exercisable at July 31, 2017:

| NUMBER OF WARRANTS | EXERCISE PRICE | EXPIRY DATE |
|-----------------------|-------------------|-------------------|
| 5,573,725 | \$0.06 | March 19, 2018 |
| 713,085 | \$0.10 | March 19, 2018 |
| 975,989 | \$0.06 | May 16, 2018 |
| 101 | \$0.10 | May 16, 2018 |
| 2,162,500 | \$0.06 | December 20, 2018 |
| 9,425,400 | | |

As at July 31, 2017, the weighted average remaining contractual life of all warrants outstanding was 0.82 years (2016 - 1.54 years). Please see Subsequent Events Note 10.

7. Share Capital and Reserve (Continued)

d) Stock Options

The Company has adopted an incentive stock option plan, which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the Canadian Stock Exchange requirements, grant to directors, officers, employees and technical consultants to the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Options will be exercisable for a period to be determined by the board of Directors, but not exceeding 10 years.

In connection with the foregoing, the number of common shares reserved for issuance to any technical consultant will not exceed two percent (2%) of the issued and outstanding common shares in any twelve month period. The number of common shares reserved for issuance to individuals providing investor relation services will not exceed two percent (2%) of issued and outstanding common shares in any twelve month period. Further, these options must vest over twelve months with a maximum of one quarter of the options vesting in any three month period. Options may be exercised no later than 30 days following cessation of the optionee's position with the Company, provided that if the cessation of office, directorship, or technical consulting arrangement was by reason of death, the option may be exercised within a maximum period of one year after such death, subject to the expiry date of such option.

During the period ended nine month period ended July 31, 2017, stock based compensation in the amount of \$744,972 (2016 – \$588,835) was recognized on the issuance of stock options to directors, officers and consultants.

The following table summarizes the options outstanding and exercisable at July 31, 2017:

| NUMBER OF OPTIONS | EXERCISE PRICE | EXPIRY DATE |
|----------------------|-------------------|-------------------|
| 500,000 | \$0.08 | May 30, 2021 |
| 1,000,000 | \$0.065 | February 27, 2022 |
| 1,500,000 | | |

As at July 31, 2017, the weighted average remaining contractual life of all options outstanding was 4.33 years (July 31, 2016 – 4.85 years).

The Company uses the Black-Scholes option pricing model to estimate the fair value of the options granted using the following assumptions:

| | NINE MONTH PERIODS ENDED JULY 31, | | |
|-------------------------|--------------------------------------|--------------|--|
| | 2017 | 2016 | |
| Dividend yield | Nil | Nil | |
| Annualized volatility | 216% - 222% | 208 - 212% | |
| Risk-free interest rate | 0.91% - 1.02% | 0.61 – 0.73% | |
| Expected life | 5 years | 5 years | |

See Subsequent Events (Note 10).

7. Share Capital and Reserve (Continued)

e) Loss Per Share

Basic loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. The basic and diluted loss per share are the same as there are no instruments that have a dilutive effect.

| | THREE MON | | NINE MONTH PERIODS ENDED JULY 31, | | |
|--------------------------------------|------------|------------|--------------------------------------|------------|--|
| | ENDED . | , | | | |
| | 2017 | 2016 | 2017 | 2016 | |
| | | | | | |
| Issued shares at beginning of period | 76,748,146 | 52,897,816 | 63,342,146 | 51,966,972 | |
| Weighted average issuances | 1,332,145 | 5,303,488 | 7,950,680 | 2,399,031 | |
| Basic weighted average common shares | 78,080,291 | 58,201,304 | 71,292,826 | 54,366,003 | |

f) Nature and Purpose of Reserve

The 'Share-based Payment Reserve' is used to recognize the fair value of stock option grants and warrants prior to exercise, expiry or cancellation.

g) Share Subscriptions

During the period ended July 31, 2016, the Company received \$56,750 relating to share subscriptions receivable as at October 31, 2015.

During the period ended July 31, 2017, the Company received \$193,200 relating to the private placement financing announced July 14, 2017 and subsequently amended August 24, 2017.

8. Related Party Transactions

All related party transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments.

a) Related party transactions with directors and companies with a director in common.

| | NINE MONTH PERIODS ENDED JULY 31, | | | |
|--|--------------------------------------|------------------|----|---------------------|
| | | 2017 2016 | | |
| Management fees | \$ | 60,390 | \$ | 42,381 |
| Consulting fees | \$ | 18,810 | \$ | - |
| b) Advances payable | | JULY 31, 2017 | | OCTOBER 31, 2016 |
| Advances from directors are unsecured, non- interest bearing and is repayable on demand | \$ | 100,578 | \$ | 102,278 |

8. Related Party Transactions (Continued)

c) Management compensation

| , management compensation | NINE MONTH PERIODS ENDED JULY 31, | | | |
|--------------------------------|--------------------------------------|---------|----|--------|
| | | 2017 | | 2016 |
| Short-term management benefits | \$ | 60,390 | \$ | 42,381 |
| Consulting fees | \$ | 18,410 | \$ | - |
| Share-based payments | \$ | 238,830 | \$ | 78,428 |

9. Non-Cash Investing and Financing Transactions

Investing and financing activities that do not have a direct impact on current cash flows are excluded from the statements of cash flows.

Nine month period ended July 31, 2017:

\$868,404 was transferred from share based payment reserves to share capital as a result of the exercise of 12,730,000 stock options at prices between \$0.05 and \$0.08.

Nine month period ended July 31, 2016:

\$359,079 was transferred from share based payment reserves to share capital as a result of the exercise of 6,985,000 stock options at prices between \$0.05 and \$0.08.

10. Subsequent Events

Subsequent to July 31, 2017, the Company:

- Issued 2,625,000 common shares for the exercise of 2,625,000 warrants at \$0.06 per share for total proceeds of \$157,500;
- Issued 200,000 common shares for the exercise of 200,000 options at \$0.065 per share for total proceeds of \$13,000 which resulted in a transfer from share-based payment reserve to share capital of \$13,826;
- Issued 43,700,000 units at a price of \$0.06 per unit for gross proceeds of \$2,622,000 through a non-brokered private placement. Each unit consists of one common share in the capital of the Company and one common share purchase warrant. Each warrant will entitle the holder to purchase one additional common share at a purchase price of \$0.10 until August 30, 2019. The Company paid cash commission of \$91,900 and issued 1,531,653 finder's warrants In connection with the private placement. Each finder's warrant entitles the holder to purchase one common share until August 30, 2019.
- completed the acquisition of an additional 25% interest in PhyeinMed Inc., a late stage Health Canada Access to Cannabis for Medical Purposes Regulations ("ACMRP") applicant for the purpose of growing, selling and distributing medical cannabis. The Company now owns 75% of the issued and outstanding common shares of PhyeinMed.

(Unaudited)

10. Subsequent Events (Continued)

In consideration for the acquisition and pursuant to the terms of the Share Purchase Agreement, the Company:

- paid a total of \$100,000 (an additional \$20,000 will be paid upon completion by the Company of equity financings that have raised gross proceeds of at least \$1,500,000);
- issued 7,000,000 common shares in the capital of the Company. The shares are subject to a four month hold period under applicable securities laws expiring on December 19, 2017, and are also subject to a voluntary escrow period pursuant to which 10% of the Shares were released immediately and an additional 15% of the Shares will be released every six months from the closing date;
- will issue an additional 4,000,000 shares upon final award of an ACMPR production license;
- granted 2,000,000 stock options to the President of PhyeinMed to acquire up to 2,000,000 common shares at an exercise price of \$0.10 per common share until August 16, 2022;
- awarded 2,400,000 restricted stock units ("RSU's") to the president of PhyeinMed and an additional 1,600,000 RSU's to other eligible recipients. Half of the RSU's vest immediately upon the grant date while the remaining RSU's vest in 12 months from the grant date; and
- committed up to an additional \$3,000,000 to fund PhyeinMed's efforts in the medical marijuana business.
- Announced a RSU plan for directors, executive officers, employees and consultants of the Company was approved by the board of directors. Ratification of the RSU plan is subject to the approval of the Company's shareholders.
- Completed the purchase of a property in Falkland, BC for the purposes on cannabis production. The property includes 13 acres of land, structures with 10,500 sq. ft. of potential grow area and a stand-alone administrative building. The purchase price of the land was \$995,000 and the Company paid an additional \$23,884 in applicable taxes and selling fees.